Recent research indicates that either empagliflozin or dapagliflozin have comparable long-term kidney outcomes.[10] The guidelines of the International Society of Amyloidosis indicated that for amyloidosis patients with proteinuria, the addition of sodium-glucose cotransporter 2 inhibitors could be considered.[11] In this case, empagliflozin was the preferred agent. Here, SLC5A2 is linked to amyloidosis.